
Tezepelumab significantly improved patients’ perception of asthma triggers, reducing symptoms and enhancing quality of life. In this 30-patient study, improvements were noted in "air pollution" and "infection" trigger domains. After 3 months, correlations between asthma triggers and quality of life showed promising results, suggesting tezepelumab's role in managing asthma hypersensitivity. More research is needed to explore long-term impacts and underlying mechanisms.
Like
Save
Share